Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis.
Seventeen diabetic patients with moderate to mild foot lesions associated with 20 osteomyelitic bones diagnosed by both bone scan and bone biopsy received rifampicin plus ofloxacin for a median duration of 6 months. Cure was defined as disappearance of all signs and symptoms of infection at the end of the treatment and absence of relapse during follow up. At the end of the treatment period, cure was achieved in 15 patients (88.2%) and was maintained in 13 patients (76.5%) at the end of an average post-treatment follow-up of 22 months. No serious drug-related adverse events were recorded.
Senneville
E
E
Service des Maladies Infectieuses et Tropicales, Hôpital Dron, 135 rue du Pr Coty, F-59200 Tourcoing, France. esenneville@ch-tourcoing.fr
Yazdanpanah
Y
Y
Cazaubiel
M
M
Cordonnier
M
M
Valette
M
M
Beltrand
E
E
Khazarjian
A
A
Maulin
L
L
Alfandari
S
S
Caillaux
M
M
Dubreuil
L
L
Mouton
Y
Y
D000284:Administration, Oral; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002908:Chronic Disease; D017719:Diabetic Foot / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D015242:Ofloxacin; D012293:Rifampin